Divi's Laboratories Q1 FY25 results (Apr–Jun 2024) and concall

Divi's opened FY25 with solid 18% constant currency growth driven by balanced performance across generics and custom synthesis. Generics contributed 51% reflecting strong volume momentum despite persistent pricing headwinds. Kakinada Phase 1 construction progressing with commercialization expected by FY25-end. The company maintained its strong cash position of ₹4,229 crores while investing in backward integration and peptide capabilities.